医学
瞬态弹性成像
肝细胞癌
队列
内科学
弗雷明翰风险评分
列线图
乙型肝炎病毒
肿瘤科
胃肠病学
纤维化
疾病
肝纤维化
免疫学
病毒
作者
Chan Tian,Chunyan Ye,Haiyan Guo,Kun Ping Lu,Jing Wang,Xinghuan Wang,Xinyuan Ge,Chengxiao Yu,Jing Lü,Longfeng Jiang,Qun Zhang,Ci Song
摘要
Abstract Background & Aims Liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE) accurately assesses fibrosis. We aimed to develop a universal risk score for predicting hepatocellular carcinoma (HCC) development in patients with chronic hepatitis. Methods We systematically selected predictors and developed the risk prediction model (HCC-LSM) in the HBV training cohort (n = 2,251, median follow-up of 3.2 years). The HCC-LSM model was validated in an independent HBV validation cohort (n = 1,191, median follow-up of 5.7 years) and a non-viral chronic liver disease (CLD) extrapolation cohort (n = 1,189, median follow-up of 3.3 years). A HCC risk score was then constructed based on a nomogram. An online risk evaluation tool (LEBER) was developed using ChatGPT4.0. Results Eight routinely available predictors were identified, with LSM levels showing a significant dose-response relationship with HCC incidence (P < .001 by log-rank test). The HCC-LSM model exhibited excellent predictive performance in the HBV training cohort (C-index = 0.866) and the HBV validation cohort (C-index = 0.852), with good performance in the extrapolation CLD cohort (C-index = 0.769). The model demonstrated significantly superior discrimination compared to six previous models across the three cohorts. Cut-off values of 87.2 and 121.1 for the HCC-LSM score categorized participants into low-, medium-, and high-risk groups. An online public risk evaluation tool (LEBER; http://ccra.njmu.edu.cn/LEBER669.html) was developed to facilitate the use of HCC-LSM. Conclusion The accessible, reliable risk score based on LSM accurately predicted HCC development in patients with chronic hepatitis, providing an effective risk assessment tool for HCC surveillance strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI